Cargando…

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis

Anti-MDA5 antibodies-associated amyopathic dermatomyositisis a rare autoimmune disease that involve polyarthritis, cutaneous and pulmonary manifestations. The development of rapidly progressing interstitial lung disease is a life-threatening complication. We report the case of a 45-year-old woman wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aissaoui, Houari, Alsibai, Kinan Drak, Khayath, Naji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167562/
https://www.ncbi.nlm.nih.gov/pubmed/33922105
http://dx.doi.org/10.3390/clinpract11020035
_version_ 1783701717042331648
author Aissaoui, Houari
Alsibai, Kinan Drak
Khayath, Naji
author_facet Aissaoui, Houari
Alsibai, Kinan Drak
Khayath, Naji
author_sort Aissaoui, Houari
collection PubMed
description Anti-MDA5 antibodies-associated amyopathic dermatomyositisis a rare autoimmune disease that involve polyarthritis, cutaneous and pulmonary manifestations. The development of rapidly progressing interstitial lung disease is a life-threatening complication. We report the case of a 45-year-old woman without medical history, who was addressed to the Pulmonary Department for a polyarthritis with dry cough and hypoxemic dyspnea. Initially there was neither cutaneous manifestation nor interstitial lung disease on chest CT scan. After a few days, the patient developed fatal acute respiratory failure with diffuse ground glass opacities. Identification of anti-MDA5 antibodies allowed establishing diagnosis, despite the fact that the first immunological assessment was negative. Corticosteroid bolus of 1 g for three days and immunosuppressive treatment by cyclophosphamide was only initiated at the acute respiratory distress syndrome stage. Given the rapidly unfavorable prognosis of this entity of amyopathic dermatomyositis, the testing for anti-MDA5 antibodies should be recommended in case of progressive pulmonary symptoms associated with joint signs in order to identify this disease at an early stage and to begin rapid and adequate management.
format Online
Article
Text
id pubmed-8167562
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81675622021-06-02 Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis Aissaoui, Houari Alsibai, Kinan Drak Khayath, Naji Clin Pract Case Report Anti-MDA5 antibodies-associated amyopathic dermatomyositisis a rare autoimmune disease that involve polyarthritis, cutaneous and pulmonary manifestations. The development of rapidly progressing interstitial lung disease is a life-threatening complication. We report the case of a 45-year-old woman without medical history, who was addressed to the Pulmonary Department for a polyarthritis with dry cough and hypoxemic dyspnea. Initially there was neither cutaneous manifestation nor interstitial lung disease on chest CT scan. After a few days, the patient developed fatal acute respiratory failure with diffuse ground glass opacities. Identification of anti-MDA5 antibodies allowed establishing diagnosis, despite the fact that the first immunological assessment was negative. Corticosteroid bolus of 1 g for three days and immunosuppressive treatment by cyclophosphamide was only initiated at the acute respiratory distress syndrome stage. Given the rapidly unfavorable prognosis of this entity of amyopathic dermatomyositis, the testing for anti-MDA5 antibodies should be recommended in case of progressive pulmonary symptoms associated with joint signs in order to identify this disease at an early stage and to begin rapid and adequate management. MDPI 2021-04-22 /pmc/articles/PMC8167562/ /pubmed/33922105 http://dx.doi.org/10.3390/clinpract11020035 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Case Report
Aissaoui, Houari
Alsibai, Kinan Drak
Khayath, Naji
Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
title Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
title_full Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
title_fullStr Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
title_full_unstemmed Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
title_short Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
title_sort fast-onset diffuse interstitial lung disease in anti-mda5 antibodies-associated amyopathic dermatomyositis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167562/
https://www.ncbi.nlm.nih.gov/pubmed/33922105
http://dx.doi.org/10.3390/clinpract11020035
work_keys_str_mv AT aissaouihouari fastonsetdiffuseinterstitiallungdiseaseinantimda5antibodiesassociatedamyopathicdermatomyositis
AT alsibaikinandrak fastonsetdiffuseinterstitiallungdiseaseinantimda5antibodiesassociatedamyopathicdermatomyositis
AT khayathnaji fastonsetdiffuseinterstitiallungdiseaseinantimda5antibodiesassociatedamyopathicdermatomyositis